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Copeptin, a glycosylated peptide fragment derived from the C-terminal region of the 
precursor of arginine8 vasopressin (AVP), is co-secreted with AVP in equimolar 
amounts. Elevated plasma AVP modulates gastric motility so we investigated 
whether copeptin had a similar effect. 
Copeptin (10-9-10-7M), and AVP (10-12-10-5M), were evaluated for their ability to 
modulate spontaneous and electrically-evoked (EFS) contractions of human 
proximal and distal gastric circular muscle in vitro. Similar experiments were 
performed on the mouse stomach and we re-examined the published effect of 
copeptin on the mouse aorta. 
In the presence of tetrodotoxin (10-6M), atropine (10-6M) and L-NAME (3x10-4M), 
human proximal and distal stomach muscle contracted spontaneously and 
rhythmically as did mouse distal stomach.  
Copeptin (10-9-10-7M), had no effect on baseline muscle tone or myogenic 
spontaneous contractions of either human or mouse stomach. However, AVP 
concentration-dependently increased tone, amplitude and frequency of contractions 
in both regions of human stomach with similar potency (pEC50 9.0-9.5; n=4) and 
threshold concentration (10-11-10-10M). AVP was similarly active in the mouse 
stomach. EFS-evoked cholinergic contractions (human and mouse) were unaffected 
by both peptides EFS-evoked relaxations of mouse stomach were  unaffected by 
copeptin.  
In sub-maximally contracted mouse aorta the elevated tone was unaffected by 
copeptin (10-7M) (cf. previously published study) but was reduced by carbachol (10-
6M) and sodium nitroprusside (10-3M). 
We conclude that in contrast to AVP, copeptin over a concentration range reported in 
the plasma has no direct ability to modulate the motility of the human and mouse 
stomach.  
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Copeptin is a 39-amino acid fragment derived from the C-terminal region of the 
precursor of arginine8 vasopressin (AVP; anti-diuretic hormone, ADH), pre-pro-AVP 
(Holwerda, 1972). It is secreted from the posterior pituitary with AVP in equimolar 
amounts in response to plasma hyperosmolality, low blood volume or pressure 
(Christ-Crain, 2019; Dobša & Edozien, 2013; Morgenthaler et al., 2006).  
In humans, >90% of the released AVP is bound to platelets (Preibisz et al., 1983) 
and inactivated in the liver and kidney (Baumann & Dingman, 1976; Dobša & 
Edozien, 2013). This renders AVP with a short half-life (4-20 min) (Christ-Crain, 
2019; Treschan & Peters, 2006) in vivo. In comparison, copeptin is metabolically 
stable with a longer half-life (~90 min) (Beglinger et al., 2017) and mirrors the 
released concentration of AVP (Dobša & Edozien, 2013; Morgenthaler et al., 2006). 
Consequently, copeptin has been used as a prognostic and diagnostic biomarker of 
diseases and disorders associated with imbalances in AVP (Christ-Crain, 2019; 
Dobša & Edozien, 2013). Its use has also been extended to investigations into the 
heightened release of AVP in response to stressful stimuli such as strenuous 
exercise (Hew-Butler et al., 2011; Popovic et al., 2019), pregnancy (Evers & 
Wellmann, 2016) and surgery (Mastropietro et al., 2012). These studies have 
confirmed a positive correlation between the plasma concentration of both peptides, 
and a parallel 2-10 fold rise in their values above physiological levels (~1-10 pg/ml). 
Notably, additional stressful stimuli such as heat (Pittman & Wilkinson, 1992), 
numerous medications (Andrews & Hawthorn, 1988; Belton & Thomas, 1999; Chan, 
1997; Edwards et al., 1989, Feldman et al., 1988; Fisher et al., 1982; Raskind et al., 
1987; Shepshelovich et al., 2017), sensory irritants (Bester-Meredith et al., 2015; 
Wacker & Ludwig, 2019), vection (Farmer et al., 2015; Kim et al.,1997; Koch et al., 
1990; Xu et al., 1993) are associated with a 2-200 fold rise in the basal plasma level 
of AVP. Whilst copeptin has not been measured under the same circumstances, its 
concentration is likely to have been similarly increased in these studies raising the 
question of whether copeptin could be responsible for biological effects ascribed to 
the elevated AVP.  
Remarkably, despite the discovery of copeptin ~50 years ago (Holwerda, 1972), the 
physiological function and consequence of elevated copeptin is unknown. One 
suggestion is that it may be involved in the structural formation of pre-pro-AVP 
(Morgenthaler et al., 2008). However, it seems reasonable to hypothesise that 
copeptin might also have activity among those functions in which AVP is known to 
play a role. For example, there is strong association between raised plasma AVP, 
the sensation of nausea and disruptions in the myoelectrical “slow wave” rhythm of 
the stomach (Koch, 1997; Stern et al., 2011). Further, nausea is reported by patients 
receiving AVP or its analogs (e.g. terlipressin) for treatment of gastric bleeding and 
diabetic insipidus (Stump & Hardin, 1990), and when AVP is administered 
experimentally in healthy volunteers (Caras et al., 1997). It is hypothesised that one 
way in which AVP could induce nausea is by disruption of gastric motility (Makwana 
et al., 2018; Stern et al., 2011). However, copeptin could be equally responsible. It is 
not known whether copeptin can modulate gastric motility in a similar manner but 
acute exposure of the mouse aorta to copeptin is reported to relax the smooth 
muscle (Rasor et al., 2006) raising the possibility that it may modulate gastric smooth 
muscle function. 
We have now investigated whether copeptin could modulate human gastric motility 
at concentrations comparable to AVP, tested as a positive control. As a further 
control we also performed similar experiments on the mouse isolated stomach and in 
an attempt to replicate previously reported findings with copeptin we also studied the 
mouse aorta (Rasor et al., 2006). 
2. Materials and methods 
2.1. Tissues 
2.1.1 Human stomach 
Human stomach tissue was obtained from obese patients (1 male and 7 females, 
median age 43 years, mean body mass index (BMI) 47.7  2.8 kg/m2) undergoing 
vertical sleeve gastrectomy. Two of the 8 donors were diagnosed with Type 2 
diabetes and there was no evidence of additional co-morbidities. Written, informed 
consent was obtained from all donors in accordance with the requirements of the 
local ethics committee (QMUL REC 15/LO/2127). The resected specimen was cut 
~2cm from the gastro-oesophageal junction and up to ~8 cm from the pylorus and 
approximately two-thirds of width between the curvatures. Sections of ~5 cm2 were 
cut 5 cm from both ends of the specimen, excluding the areas clearly damaged 
during surgery. These sections represented the fundus-proximal corpus and antrum-
distal corpus, respectively, and for concision are referred to as the proximal and 
distal stomach hereafter.  
Stomach sections were transported to the laboratory within 1 hr after resection in 
Krebs-Henseleit solution (x10-3M: NaCl 118.3, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25, D-glucose 11.1, CaCl2 2.5) pre-gassed with 95% O2 and 5% CO2.  The 
mucosa, muscularis mucosa and submucosal plexus were removed by blunt 
dissection and discarded.  A maximum of four strips (5 x 20 mm) were cut 
perpendicular to the greater curvature, approximately parallel to circular muscle 
fibres from each region. Detailed methods for collecting and minimising variation 
when using human gastrointestinal tissue have been previously described (Sanger et 
al., 2013). 
Tissues were studied on the following day after overnight (15-18 h) storage in Krebs- 
Henseleit at 4ºC in pre-oxygenated Krebs-Henseleit solution. Previously, electrically-
evoked and agonist-evoked contractions have been found not to be affected by 
overnight storage (Broad et al., 2011). 
 
2.1.2 Mouse stomach and aorta 
Animal care and welfare complied with the UK Animals Scientific Procedures (ASPA) 
Act 1986 Code of Practice and the European Directive 2010/63 provisions as 
transposed into the UK. Male and female virgin CD1 mice (25-30g, 7 weeks old) 
were purchased from Charles River Laboratories (Margate, UK) and housed in a 
room with a controlled temperature (22±1°C), humidity (55±10%) and 12-h light-dark 
cycle. Both sexes were segregated in separate cages with food (LabDiet® 
EURodent diet 14%, International Product Supplies Ltd, London, UK) and water 
provided ad libitum until sacrifice, and were used after a minimum of 6 days 
acclimatisation. The collection of cadaveric tissue did not require ASPA authority, 
and all humane killing by ASPA Schedule 1 methods was conducted within Queen 
Mary University of London, a UK Home Office licenced establishment (Ref 
XEDA0E7B1). Mice were killed by a Schedule 1 method that consisted of cervical 
dislocation followed by exsanguination to ensure death. The protocol was approved 
by the Animal welfare ethical review board for Queen Mary University of London and 
those involved were trained and signed off as competent by the Named Training and 
Competency Officer and Named Animal Care and Welfare Officer.  
The stomach and thoracic aorta were excised and immersed in Krebs-Henseleit 
solution at room temperature (~20OC). After removal of adherent connective tissue, 
ring preparations (3 mm wide) were cut from the proximal (forestomach) and distal 
(corpus-antrum) stomach along the axis of the circular muscle fibres.  The aorta was 
divided into two rings (5 mm in length). Tissues were used immediately for functional 
experiments. 
 
2.1.3 Assay procedure 
The test apparatus has been described previously (Broad et al., 2011). Briefly, 
tissues were suspended in 10 ml tissue baths between platinum wire electrodes (15 
mm length, 10mm apart) and an isometric force transducer (MLT201/D, AD 
Instruments, Chalgrove, UK) using cotton thread for human stomach strips or L-
shaped stainless steel wires for mouse stomach and aortic rings. The bath was filled 
with Krebs-Henseleit solution, gassed with 95% O2 and 5% CO2 and maintained at 
37⁰C. Changes in muscle tension was recorded in milliNewtons (mN) on a Dell 
personal computer (Dell, UK, www.dell.com/uk) using AcqKnowledge v3.8.1 
recording software (BIOPAC Systems Inc., CA, USA). Both freshly dissected tissues 
at room temperature and those that had been stored overnight at 4OC were initially 
suspended in the baths for 15 min without tension and allowed to equilibrate to the 
temperature of the bath. The human stomach strips and mouse tissues (stomach 
and aortic rings) were then stretched by 20 mN and 10mN, respectively, and allowed 
to equilibrate under tension for at least 60 mins until rhythmic uniform-sized 
spontaneous contractions and/or a stable baseline tone was recorded. Drug 
treatments were commenced after a minimum of 30 min of stable tone and/or 
contractions. During this period, the Krebs-Henseleit solution was renewed at 20 min 
intervals.  
The action of copeptin (10-9 – 10-7 M) and AVP (10-12 – 10-5 M) was examined on the 
contractions of stomach tissues elicited by electrical field stimulation (EFS) and 
during blockade of neuronal activity by addition of tetrodotoxin (10-6 M), atropine (10-
6 M) and L-NAME (3x10-4 M) to the bathing solution for inhibition of the voltage-
dependent Na+ channel mediating action potentials, antagonism at muscarinic 
acetylcholine receptors and inhibition of nitric oxide synthase activity, respectively. 
EFS was applied by using a STG2008 stimulator (Multi Channel Systems, 
Reukingen, Germany), with a volley of pulses of 5 Hz frequency, 0.5 ms pulse width, 
for 10 s every 1 min at a voltage 10% greater than that required for EFS to elicit a 
maximal contraction. Test compounds were applied cumulatively in log-unit 
increments with a 15 min dosing interval, or when the effect of the previous 
concentration had peaked. Only one concentration-response curve was constructed 
per tissue. Copeptin could not be investigated at concentrations greater than 10-7 M 
because of its poor solubility. Nevertheless, this concentration would have been 
equivalent to a concentration 4000 fold greater than the maximal plasma 
concentration reported in vivo (Christ-Crain, 2019; Dobša & Edozien, 2013). 
All experiments were performed in parallel with relevant vehicle-treated and time-
matched controls. After completion of an experiment, stomach tissues were 
challenged with a supramaximal concentration of carbachol (10-3 M) in order to 
compare their integrity and rule out concerns about potential damage resulting from 
the surgery and dissection. The response to carbachol also served as a comparator 
to standardise the action of the test compounds on the stomach muscle from each 
species. 
After the equilibration period, the maximal contractile capacity of each aortic ring was 
assessed in response to potassium chloride (KCl 8 x 10-2M; Chataigneau et al., 
1999). Following a wash with drug-free Krebs-Henseleit solution and a 15 min period 
recovery to the initial basal muscle tension, aortic rings were stimulated with either 
noradrenaline (10-6M) or  KCl (5 x 10-2M) in order to elicit a stable elevated muscle 
tone representing ~65-70% of the reference contraction to KCl (8 x 10-2M,). The 
ability of copeptin (10-7M) to relax the contracted aortic rings was then investigated, 
followed by an application of carbachol (10-3M) to elicit an endogenous nitric oxide-
mediated relaxation as a means to verify the integrity of the endothelium. At the end 
of the experiment, sodium nitroprusside (SNP, 10-3M), a nitric oxide donor, was 
applied to the aortic rings to elicit maximal relaxation of the muscle.  
2.2, Data analysis and Statistics  
For experiments in which tissues were stimulated electrically, the effect of an agonist 
was quantified as a percentage change in amplitude of EFS-evoked contractions 
determined immediately before its first addition. Spontaneous contractions in the 
absence and presence of an agonist were quantified by measuring the change in 
basal muscle tone (mN), amplitude of spontaneous contractions (mN) and frequency 
of contractions per min (c/min) during a steady-state period. The increase in baseline 
muscle tension (tone) of the gastric muscle in response to the test molecule was also 
expressed as a percentage of the amplitude of contraction evoked by carbachol. 
Contractions of the aortic rings in response to noradrenaline (10-6M) and KCl (5x10-
2M), were expressed as a percentage of the maximal contraction in response to KCl 
(8x10-2M). Relaxation of the noradrenaline and KCl contracted aortic rings were 
expressed as a percentage of the maximal relaxation in response to SNP (10-3M). 
All agonist concentration-response data were quantified as mean ± standard error of 
the mean (mean ± S.E.M). Individual agonist concentration-response curves were 
fitted by non-linear regression to a four-parameter logistic Hill equation using 
GraphPad PRISM 8.0 for Windows (Graph-Pad Software, La Jolla, CA, USA) as 
described previously (Makwana et al., 2010). 
Where appropriate, a paired or unpaired Student’s t-test was performed for 
comparisons of individual means of data from within a given type of tissue or 
between tissues from different donors, respectively, followed by a Dunnett’s post hoc 
test for multiple comparisons. The probability P < 0.05 was taken to be statistically 
significant. n values represent the number of patients or animals. Only one muscle 
strip or ring was used per drug treatment from a given patient or animal. Drug and 
molecular target nomenclature conform to the IUPHAR / British Journal of 
Pharmacology Guide to Receptors and Channels (Alexander et al., 2019). 
2.3. Materials 
Atropine sulphate, Ascorbic acid, Carbachol (carbamylcholine chloride), Copeptin 
trifluoroacetate (human), L-NAME (Nω-nitro-L-arginine methyl ester hydrochloride, (-
) Noradrenaline, SNP (sodium nitroprusside), Tetrodotoxin and reagents for making 
the Krebs-Henseleit solution were purchased from Sigma-Aldrich, Poole, UK. AVP 
(Arginine8 vasopressin) was purchased from Tocris Biosciences, Abingdon, UK. 
Ascorbic acid, Carbachol, Copeptin, L-NAME, AVP and tetrodotoxin were dissolved 
in distilled water. Noradrenaline was dissolved in ascorbic acid (10-3M). The total 
volume of the solvents added to the tissue baths did not exceed 1% of bath volume. 
3. Results 
3.1 Electrical field stimulation (EFS)-evoked responses of human and mouse 
stomach 
EFS elicited a short-lived monophasic contraction of human proximal and distal 
stomach strips during the period of stimulation, with a similar amplitude of 17.6 ± 
1.48 mN and 18.7 ± 1.6 mN (n = 8), respectively. These represented 22.1 ± 3.1 % 
and 19.2 ± 4.2 % of the amplitude of the contraction elicited by carbachol (10-3 M, n = 
8), respectively. The EFS-evoked contractions of both stomach regions were 
unaffected by copeptin or AVP up to the highest concentrations tested i.e. 10-7 M and 
10-5 M, respectively (Fig. 1), but abolished by either TTX (10-6 M; proximal and distal 
stomach: 98.7 ± 2.4 % and 99.4 ± 1.4 %, n = 4, respectively) or atropine (10-6 M; 
proximal and distal stomach: 96.5 ± 3.4 % and 98.54 ± 2.4 % n = 4, respectively).  
In mouse proximal and distal stomach, EFS elicited a relaxation of 3.5 ± 0.3 mN and 
1.8 ± 0.4 mN (n = 8) respectively during the period of stimulation, followed by a 
“rebound” contraction of 4.8 ± 0.4 mN and 5.9 ± 0.4 mN (n = 8), respectively, on 
termination of the stimulation. Carbachol (10-3M) produced a comparable maximal 
contraction of 42.6 ± 2.8 mN and 40.4 ± 2.9 mN (n = 8 for both) of the mouse 
proximal and distal stomach, respectively. Thus, the rebound contractions were 9.5 ± 
1.48 % and 16.9 ± 2.3 % (n = 8 for both) of the amplitude of the contraction elicited 
by carbachol (10-3 M,), respectively. The EFS-evoked relaxations and rebound 
contractions of both stomach regions were unaffected by copeptin (Fig. 2) but were 
both abolished by TTX (10-6 M; (proximal and distal stomach, n=2): 94.3 and 100 % 
and 98.4 and 100% respectively). The relaxations were also abolished by L-NAME 
(3x10-4M; proximal and distal stomach: n = 2) whereas the rebound contractions 
were blocked by atropine (10-6 M; proximal and distal stomach: n = 2). 
3.2 Myogenic responses of human and mouse stomach 
Strips of both human proximal and distal stomach displayed spontaneous rhythmic 
contractions at a frequency of 2.3 ± 0.1 and 2.4 ± 0.1 per min; (n = 8), respectively. 
The contractions of the former were ~5 times smaller than those of the latter (0.9 ± 
0.2 mN vs 4.6 ± 0.4 mN; n = 8). The maximal contraction of both types of muscle 
strips in response to carbachol (10-3M) was comparable (respectively, 82.6 ± 4.2 mN 
and 87.8 ± 6.0 mN; n = 8).  Copeptin (Fig. 3A and B) in concentrations as high as 10-
7 M had no effect on the amplitude and frequency of the spontaneous contractions 
nor affected the baseline tension of muscle strips from either human stomach region. 
A longer (1 h) exposure to the highest concentration (10-7 M) did not induce any 
activity.  In contrast, AVP (10-12 – 10-5 M) produced a concentration–related increase 
in the amplitude and frequency of the spontaneous contractions and a rise in the 
baseline tension of the muscle strips from both human stomach regions (Fig. 3C and 
D). The potency of AVP (pEC50 9.0 - 9.5) and the lowest effective concentration 
tested for each effect (between 10-11 and 10-10 M) was similar in both stomach 
regions (Fig. 3 and 4).  
In mouse stomach, spontaneous contractions were produced by the muscle from the   
distal region only (Fig. 5D and D). These contractions had an amplitude of 3.1 ± 0.2 
mN and occurred at a frequency of 1.2 ± 0.2 min-1 (n = 6 for both). The amplitude of 
these contractions equated to 8.0 ± 7.6 % (n = 6) of the carbachol-induced 
contraction. Copeptin had no effect on baseline muscle tone or the spontaneous 
contractions of either region of the mouse stomach (Fig. 5 A, B and 6). In contrast, 
AVP raised the muscle tone (pEC50 7.3 ± 0.2; threshold concentration ~10-9M, n=3) 
of the proximal stomach muscle only (Fig. 5C and 6), with the maximal rise 
representing 38.7 ± 4.8 % (n=3) of the carbachol-induced contraction. AVP (Fig. 5D 
and 6) also increased the amplitude of the spontaneous contractions of the distal 
stomach (pEC50 6.0 ± 0.2; threshold concentration >10-6M, n=3) and their frequency 
(pEC50 7.3 ± 0.2, threshold concentration >10-9M, n=3). Notably, the application of 
AVP (10-7M and 10-6M) was associated with a short-lived initial reduction in 
spontaneous contraction amplitude and arrhythmic contractions of varying amplitude 
at concentrations 10-6M (Fig. 5D).  
3.3 Mouse aorta 
In mouse aorta, KCl (8x10-2M) elicited a maximal contraction of 7.6 ± 0.4 mN (n = 6). 
Following a washout, noradrenaline (10-6M) and KCl (5x10-2M) generated a 
contraction of 4.9 ± 0.4 mN and 5.5 ± 0.3 mN, respectively (Fig. 7), which equated to 
~65-70 % of the reference contraction elicited by KCl (8x10-2M). The elevated 
submaximal tone was unaffected by copeptin (10-7M) but reduced by carbachol (10-
3M) and sodium nitroprusside (10-3M). Carbachol appeared more efficacious at 
inhibiting the noradrenaline-induced contraction than that elicited by KCl. Sodium 
nitroprusside caused complete relaxation of both noradrenaline and KCl-induced 
contractions (Fig. 7 and 8). 
 
4. Discussion 
The main finding of this study was that copeptin had no effect on neuronally-
mediated contractions, basal tone or the spontaneous contractions of both the 
proximal and distal human isolated stomach. The lack of effect of copeptin occurred 
at concentrations greater than those measured as a free fraction in vivo in response 
to a range of stressful stimuli (Hew-Butler et al., 2011; Popovich et al., 2019; Evans 
& Wellmann, 2016; Mastropietro et al., 2012). Such high concentrations are unlikely 
to be released even during disorders such as the syndrome of inappropriate 
antidiuretic hormone (SIADH) that is characterised by an excessive and 
insupressible release of AVP and copeptin (Moritz,2019). As a positive control AVP 
was shown to have a positive ionotropic and chronotropic effect on the spontaneous 
contractions of both proximal and distal stomach, together with a spasmogenic 
action at concentrations comparable to those circulating in subjects reporting nausea 
and with gastric myoelectrical activity disturbances (Koch, 1997; Stern et al., 2011). 
We (Makwana et al., 2018) recently suggested that each action of AVP in human 
stomach was most likely mediated by activation of the V1A receptor.  By contrast 
AVP did not modulate the EFS-evoked, cholinergically-mediated contractions of 
human stomach muscle. Notably, in similar experiments with the stomach of different 
animal species AVP has been observed to stimulate or modulate cholinergic activity 
e.g. rat (Qin et al., 2009) and cat (Mirčić et al., 1998); suggesting a markedly 
different mechanism by which AVP can influence movements of the human stomach.  
Several epidemiological studies in humans have associated elevated circulating 
levels of copeptin with obesity, including increased risk of type 2 diabetes mellitus 
and insulin resistance (Wannamethee et al., 2015; Then et al., 2015; Enhorning et 
al., 2010; Asferg et al., 2014), but no mechanistic link has been established. Obesity 
and diabetes are also associated with altered gastric motility and emptying (Marathe 
et al., 2016; Wisén & Hellström, 1995; Wright et al., 1983; Xing & Chen, 2004). This 
raises the possibility that the failure to observe a response to copeptin in stomach 
preparations from obese people was because any mechanism of activity may have 
become desensitised or downregulated during chronic exposure to endogenous 
copeptin in situ.  In our study, although 2 out of the 8 donors had been diagnosed 
with type 2 diabetes, there was no apparent difference in the spontaneous and EFS–
evoked contractions or responsiveness of the muscle to AVP between diabetic and 
non-diabetic stomachs. Thus, the incidence of diabetes was unlikely to be a 
confounding factor in the lack of effect of copeptin on the stomach. Because we did 
not have access to stomach tissue from non-obese people, comparative experiments 
were performed on the stomach from mice of normal weight. Whilst the results 
cannot exclude any confounding issues related to species differences, the finding 
that copeptin was also without effect on both neuronal and myogenic contractions 
and basal tone of mouse stomach provided a basis for suggesting that the inability of 
copeptin to exert activity in human stomach was not due to the use of tissue from 
obese people. As with human stomach, AVP also facilitated spontaneous contractile 
activity of the mouse stomach (without affecting EFS-evoked contractions) albeit less 
potently and exhibiting region- and concentration- dependent actions.  
In light of the absence of an effect of copeptin on the gastric muscle of human and 
mouse, we examined the action of copeptin on the mouse aorta as a potential 
positive control (Rasor et al., 2006). In this tissue, the peptide (10-7M) has previously 
been reported to cause a partial (~45%) endothelium-dependent and nitric oxide-
mediated relaxation (Rasor et al., 2006). However, we found that the peptide did not 
elicit a relaxation of both agonist- and receptor-dependent (noradrenaline) and 
independent (KCl) mechanisms in endothelium intact aortic rings.  
In conclusion, the present study was unable to demonstrate an ability of copeptin to 
influence the motility in proximal and distal regions of the human or mouse isolated 
stomach at concentrations comparable to AVP and greater than copeptin 
concentrations measured in the plasma. An excitatory activity of AVP acted as a 
positive control. Further, we were unable to confirm an ability of copeptin to relax 
mouse aorta muscle. To date, no other studies are reported in which the functions of 
acutely-applied copeptin have been examined. A preliminary recent study with 
copeptin (10-7M) at concentrations substantially greater than those recorded in 
human plasma,  suggested an ability to increase mRNA expression of the early 
transcriptional activation marker c-FOS in three different cell types (HEK293, 
KATOIII, and ARPE19), indicating the potential for a biological  action (Haddock et 
al., 2017). Further studies are needed to investigate the possibility that copeptin may 
be more than just a surrogate marker for AVP, responsible only for ensuring the 
correct structural formation of pre-pro-AVP (Morgenthaler et al., 2008). However, the 
results of the present study would appear to preclude an involvement in gastric 
motility modulation. 
5. Conclusion 
Copeptin has no direct ability to modulate motility of the human stomach. 
Acknowledgments 
The authors are grateful to Ms Ellie Crawley, Dr. Marilisa Straface and Ms. Hazel 
Rowson for their administrative assistance.  
5. References 
Alexander SPH, Christopoulos A, Davenport AP et al., (2019) The Concise Guide To 
Pharmacology 2019/20: G protein‐coupled receptors. Br J Pharmacol 176; S1; S21-
S14. doi: 10.1111/bph.14748. 
Andrews PLR & Hawthorn J (1988). The neurophysiology of vomiting. Clinical 
Gastroenterology 2: 141-168. doi: 10.1016/0950-3528(88)90025-5. 
Asferg CL, Andersen UB, Linneberg A et al. (2014) Copeptin, a surrogate marker for 
arginine vasopressin secretion, is associated with higher glucose and insulin 
concentrations but not higher blood pressure in obese men. Diabetic Medicine, 31, 
728–732.  doi: 10.1111/dme.12411. 
Baumann G, Dingman JF (1976). Distribution, blood transport, and degradation of 
antidiuretic hormone in man. J Clin Invest 57:1109-1116. doi: 10.1172/JCI108377. 
Beglinger S, Drewe J, Christ-Crain M (2017). The Circadian Rhythm of Copeptin, the 
C-Terminal Portion of Arginine Vasopressin. J Biomarkers, 2017, 4737082. doi: 
10.1155/2017/4737082. 
Belton K & Thomas SHL (1999). Drug-induced syndrome of inappropriate antidiuretic 
hormone secretion. Postgrad Med J 75:509–510.  doi: 10.1136/pgmj.75.886.509 
Bester-Meredith JK, Fancher AP, Mammarella GE (2015). Vasopressin proves es-
sense-tial:vasopressin and the modulation of sensory processing in mammals Front 
Endocrinol (Lausanne). 5;6:5. doi: 10.3389/fendo.2015.00005. 
Broad J, Mukherjee S, Samadi M et al., (2011) Regional- and agonist-dependent 
facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J 
Pharmacol 167:763–774. doi: 10.1111/j.1476-5381.2012.02009.x. 
Caras SD, Soykan I, Beverly Vet al., (1997). The effect of intravenous vasopressin 
on gastric myoelectrical activity in human subjects. Neurogastroenterol Motil ;9:151-
156. doi: 10.1046/j.1365-2982.1997.d01-37.x.  
Chan TY (1997). Drug-induced syndrome of inappropriate 
antidiuretic hormone secretion. Causes, diagnosis and management. Drugs 
Aging. 11(1):27-44. doi: 10.2165/00002512-199711010-00004. 
Chataigneau T, Félétou M, Huang PL et al., (1999), Acetylcholine-induced relaxation 
in blood vessels from endothelial nitric oxide synthase knockout mice. Br J 
Pharmacol. 126(1):219-226. doi: 10.1038/sj.bjp.0702300. 
Christ-Crain M (2019). Vasopressin and Copeptin in health and disease. Rev Endocr 
Metab Disord 20, 283–294. doi: 10.1007/s11154-019-09509-9. 
Dobša L & Edozien KC (2013). Copeptin and its potential role in diagnosis and 
prognosis of various diseases. Biochemia Medica 23(2):172–190.  doi: 
10.11613/bm.2013.021. PMID: 23894863 
Edwards CM, Carmichael J, Baylis PH et al., (1989).  Arginine vasopressin--a 
mediator of chemotherapy induced emesis? Br J Cancer. 59:467–470.  doi: 
10.1038/bjc.1989.96. 
Enhorning S, Wang TJ, Nilsson, PM et al. (2010) Plasma copeptin and the risk of 
diabetes mellitus. Circulation. 121, 2102–2108. doi: 
10.1161/CIRCULATIONAHA.109.909663. 
Enhorning S, Bankir L, Bouby N. et al. (2013) Copeptin, a marker of vasopressin, in 
abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and 
Cancer Study cardiovascular cohort. Int J Obesity, 37, 598–603.  doi: 
10.1038/ijo.2012.88. 
Evers KS & Wellmann S (2016). Arginine Vasopressin and Copeptin in Perinatology. 
Frontiers in Pediatrics. Volume 4. Article 75.  doi: 10.1038/ijo.2012.88. 
Farmer AD, Ban VF, Coen SJ (2015). Visually induced nausea causes characteristic 
changes in cerebral, autonomic and endocrine function in humans. J Physiol 
1;593(5):1183-96. doi: 10.1113/jphysiol.2014.284240 
Feldman M, Samson WK, O’Dorisio TM (1988). Apomorphine-induced nausea in 
humans: release of vasopressin and pancreatic polypeptide. Gastroenterology. 
95:721–726.  doi: 10.1016/s0016-5085(88)80020-9. 
Fisher R, Rentschler R, Nelson J, et al. (1982). Elevation of plasma antidiuretic 
hormones (ADH) associated with chemotherapy induced emesis in man. Cancer 
Treat Rep 66: 25–29 
Haddock CJ, Wille HM, Yosten GLC et al., (2017) Copeptin: More than Just a 
Surrogate Biomarker. FASEB, Abstract Number:714.4, Volume 31, Issue 
1_supplement01 Apr 2017. 
Hew-Butler T, Hoffman M, Stuempfle K et al., (2011). Changes in Copeptin and 
Bioactive Vasopressin in Runners With and Without Hyponatremia. Clinical journal of 
sport medicine: Official journal of the Canadian Academy of Sport Medicine. 21. 211-
7.  doi: 10.1097/JSM.0b013e31821a62c2.  
Holwerda DA (1972). A glycopeptide from the posterior lobe of pig pituitaries. I. 
Isolation and characterization. Eur J Biochem. 28(3):334-339. doi: 10.1111/j.1432-
1033.1972.tb01918.x.  
Koch KL, Summy-Long J, Bingaman S et al., (1990) Vasopressin and oxytocin 
responses to illusory self-motion and nausea in man. J Clin Endocrin Metab. 
71:1269–1275.  doi: 10.1210/jcem-71-5-1269. 
Koch, K.L. (1997), A noxious trio: nausea, gastric dysrhythmias and vasopressin. 
Neurogastroenterol Motil, 9: 141-142. doi: 10.1046/j.1365-2982.1997.d01-44.x 
Kim MS, Chey WD, Owyang C, Hasler WL (1997). Role of plasma vasopressin as a 
mediator of nausea and gastric slow wave dysrhythmias in motion sickness. Am J 
Physiol.272(4 Pt 1):G853-62. doi: 10.1152/ajpgi.1997.272.4.G853. 
Makwana R, Molleman A, Parsons ME (2010). Pharmacological characterization of 
cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal 
muscle preparation. Br J Pharmacol 159(8):1608-22.  doi: 10.1111/j.1476-
5381.2009.00592.x. 
Makwana R, Kouassi MA, Elahi S et al., (2018). Increased frequency and amplitude 
of spontaneous contractions in human stomach by vasopressin acting at V1A 
receptors in low concentrations found in plasma during nausea Abstract P195. 
Proceedings of the British Pharmacological Society, London, UK. 
Marathe CS, Rayner CK, Jones KL et al., (2016). Novel insights into the effects of 
diabetes on gastric motility. Expert Rev Gastroenterol Hepatol.10(5):581-593.  doi: 
10.1586/17474124.2016.1129898. 
Mastropietro CW, Mahan M, Valentine KM et al., (2012). Copeptin as a marker of 
relative arginine vasopressin deficiency after pediatric cardiac surgery. Intensive 
Care Med. 2012 Dec;38(12):2047-54.  doi: 10.1007/s00134-012-2731-9 
Mirčić G, Janković S, Beleslin D (1998). Differences in the effects of vasopressin and 
oxytocin on feline gastric corpus motility: selective action of vasopressin on 
longitudinal muscle. Pharmacol Res 37:383-394.  doi: 10.1006/phrs.1998.0313 
Morgenthaler NG, Struck J, Alonso C et al., (2006). Assay for the Measurement of 
Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin, Clin Chem, 
52(1) 112–119. doi: 10.1373/clinchem.2005.060038. 
Morgenthaler NG, Struck J, Jochberger S et al., (2008). Copeptin: clinical use of a 
new biomarker. Trends Endocrinol Metabol;19:43-49. doi: 
10.1016/j.tem.2007.11.001. 
Moritz, M. L. (2019). Syndrome of inappropriate antidiuresis. Pediatr. Clin. North 
Am. 66, 209–226.  doi: 10.1016/j.pcl.2018.09.005. 
Pittman QJ & Wilkinson MF (1992). Central arginine vasopressin and endogenous 
antipyresis. Can J Physiol Pharmacol. 70(5):786-90. doi: 10.1139/y92-104. 
Popovic M, Timper K, Seelig E et al., (2019). Exercise upregulates copeptin levels 
which is not regulated by interleukin-1. PloS one, 14(5), e0217800 
Preibisz JJ, Sealey JE, Laragh JH et al., (1983). Plasma and platelet vasopressin in 
essential hypertension and congestive heart failure. Hypertension. 5(2 Pt 2):I129-
1138.  doi: 10.1371/journal.pone.0217800. 
Qin J, Liu K, Wang PS, Liu C. (2009). V1 receptor in ENS mediates the excitatory 
effect of vasopressin on circular muscle strips of gastric body in vitro in rats. Reg 
Peptides 157:32–36.  doi: 10.1016/j.regpep.2009.06.003. 
Raskind MA, Courtney N, Murburg MM, et al., (1987). Antipsychotic drugs 
and plasma vasopressin in normal and acute schizophrenic patients. Biol 
Psychiatry. 22(4):453-62. doi: 10.1016/0006-3223(87)90167-3. 
Rasor M, Wegman-Points, Reho JJ et al., (2006). Acute and Chronic Biological 
Effects of Copeptin on Vascular Function in Mice and Humans. FASEB, 30, No. 
1_supplement, Abstract Number lb614. 
Saleem U, Khaleghi M, Morgenthaler NG et al. (2009) Plasma carboxy-terminal 
provasopressin (copeptin): a novel marker of insulin resistance and metabolic 
syndrome. J Clin Endocrinol Met, 94, 2558–2564. doi: 10.1210/jc.2008-2278. 
Sanger GJ, Broad J, Kung V, Knowles CH. (2013) Translational neuropharmacology: 
The use of human isolated gastrointestinal tissues.  Br J Pharmacol168:28-43. doi: 
10.1111/j.1476-5381.2012.02198.x. 
Shepshelovich D, Schechter A,  Calvarysky B et al., (2017). Medication‐induced 
SIADH: distribution and characterization according to medication class. Br J Clin 
Pharmacol. 83(8): 1801–1807.  doi: 10.1111/bcp.13256. 
Stern RM, Koch KL, Andrews PLR. Nausea: Mechanisms and Management. Oxford 
University Press, (2011), NY, USA 
Stump, D.L., Hardin, T.C. (1990). The Use of Vasopressin in the Treatment of Upper 
Gastrointestinal Haemorrhage. Drugs 39, 38–53. doi: 10.2165/00003495-
199039010-00004. 
Then C, Kowall B, Lechner A et al. (2015) Plasma copeptin is associated with type 2 
diabetes in men but not in women in the population-based KORA F4 study. Acta 
Diabetologica, 52, 103–112. doi: 10.1007/s00592-014-0609-8. 
Treschan TA & Peters J (2006) The Vasopressin System. Physiology and Clinical 
Strategies Anesthesiology 105:599–612. doi: 10.1097/00000542-200609000-00026 
Wacker & Ludwig, (2019). The role of vasopressin in olfactory and visual processing. 
Cell and Tissue Research 375:201–215. doi: 10.1007/s00441-018-2867-1. 
Wannamethee SG, Welsh P, Papacosta O et al. (2015) Copeptin, Insulin 
Resistance, and Risk of Incident Diabetes in Older Men. J Clin Endocrinol Met 100, 
3332–3339. doi: 10.1210/JC.2015-2362. 
Wisén O, Hellström PM. (1995). Gastrointestinal motility in obesity. J Intern Med. 
237(4):411-418. doi: 10.1111/j.1365-2796.1995.tb01195.x 
Wright RA, Krinsky S, Fleeman C et al., (1983). Gastric emptying and obesity. 
Gastroenetrology. 84;747-751 
Xing J & Chen JD. (2004). Alterations of gastrointestinal motility in obesity. Obes 
Res. 2(11):1723-1732.  doi: 10.1038/oby.2004.213. 
Xu LH, Koch KL, Summy-Long J (1993). Hypothalamic and gastric myoelectrical 
responses during vection-induced nausea in healthy Chinese subjects. Am J Physiol. 
265(4 Pt 1):E578-84. doi: 10.1152/ajpendo.1993.265.4.E578 
  
a) Proximal   
                      
 
 Copeptin (M):     10-9M        10-8M     10-7M 
 
b) Distal   
 
 Copeptin (M):      10-9M        10-8M     10-7M 
 















Figure 1:  Electrically-evoked contractions of the circular muscle of the human isolated 
proximal (a,c)  and distal (b,d) stomach in the absence and presence of copeptin (a,b) or AVP 
(c,d). Stimulation parameters: 5Hz frequency for 10s every 1 min, 0.5 ms duration and 110% 
supramaximal voltage.  
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Figure 2: Electrically-evoked contractions (and relaxations) of the circular muscle of the mouse 
isolated proximal (a,c)  and distal (b,d) stomach in the absence and presence of copeptin (a,b) 
or AVP (c,d). Stimulation parameters: 5Hz frequency for 10s every 1 min, 0.5 ms duration and 
110% supramaximal voltage. In c and d the black bars under the snapshots of each EFS 
response indicates the period of stimulation. 
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Figure 3: Recordings of the spontaneous contractions of the circular muscle of the (a, c) 
proximal and (b,d) distal region of the human stomach in the absence and presence of 
copeptin (a and b) and arginine8 vasopressin (AVP, c and d). The muscle strips were pre-
treated with a combination of atropine (10-6M), TTX (10-6M) and L-NAME (3 x10-4M), which 
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AVP Copeptin  
Figure 4: Concentration response curves for the changes in baseline muscle tension (a.b), 
and the amplitude (c,d) and frequency (e,f) of the spontaneous contractions of the circular 
muscle of the proximal (graphs on the left) and distal (graphs on the right) region of the human 
stomach by vasopressin and copeptin. Each curve was fitted by non-linear regression 
analysis. Each symbol represents the mean ± s.e.m of n = 4. The change in baseline muscle 
tension was expressed as a percentage of the amplitude of contraction in response to 
carbachol (10-3M) whereas the potentiation of the amplitude of contraction was expressed as 
a percentage increase in amplitude of the contractions before the first addition of the peptide. 
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Figure 5: Recordings of the basal activity of the circular muscle of the (a, c) proximal and (b,d) 
distal region of the mouse stomach in the absence and presence of copeptin (a and b) and 
arginine8 vasopressin (AVP, c and d). The muscle strips were pre-treated with a combination 
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Figure 6: Concentration response curves for the changes in baseline muscle tension (a.b), 
and the amplitude (c,d) and frequency (e) of the spontaneous contractions of the circular 
muscle of the proximal (a,c) and distal (b,d,f) region of the mouse stomach by vasopressin 
and copeptin. Each curve was fitted by non-linear regression analysis. Each symbol 
represents the mean ± s.e.m of n = 3 mice. The change in baseline muscle tension was 
expressed as a percentage of the amplitude of contraction in response to carbachol (10-3M) 
whereas the potentiation of the amplitude of contraction was expressed as a percentage 
increase in amplitude of the contractions before the first addition of the peptide. The change 
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Figure 7:  Contraction of mouse aortic rings by a submaximal (~65-70 %) concentration of a) 
noradrenaline (10-6M) and b) potassium chloride (KCl, 5x10-2M) and the lack of relaxant effect 































































































Figure 8:  Relaxation of a) noradrenaline (10-6M) and b) potassium chloride (KCl, 5x10-2M) 
induced submaximal (~65-70 %) contraction of mouse aortic rings by carbachol (CCh, 10-3M) 
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Highlights 
• Copeptin is co-released in equimolar amounts with vasopressin (AVP) from the 
posterior pituitary. 
• In contrast to AVP it is not known if copeptin is biologically active on the 
stomach. 
• Copeptin at plasma concentrations was without effect on human or mouse 
stomach in vitro. 
• We were unable to replicate a published effect of copeptin to relax the mouse 
aorta. 
• Copeptin does not modulate gastric motilit in contrast to AVP implicated in 
genesis of nausea. 
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